Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016. [electronic resource]
Producer: 20180515ISSN:- 1098-6596
- Anti-Bacterial Agents -- therapeutic use
- Cephalosporins -- therapeutic use
- Clindamycin -- therapeutic use
- Erythromycin -- therapeutic use
- Humans
- Levofloxacin -- therapeutic use
- Methicillin-Resistant Staphylococcus aureus -- drug effects
- Microbial Sensitivity Tests -- trends
- Staphylococcal Skin Infections -- drug therapy
- Tetracycline -- therapeutic use
- Trimethoprim, Sulfamethoxazole Drug Combination -- therapeutic use
- United States
- Ceftaroline
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.